Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03066947 · ClinicalTrials.gov registry record · Phase 1
SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
A Phase 1 study, sponsored by BriaCell Therapeutics Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT03066947 is a Phase 1 study that has completed, run by BriaCell Therapeutics Corporation. The registered enrollment target is 24 participants.
The verdict
NCT03066947, a Phase 1 study, has completed, sponsored by BriaCell Therapeutics Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a single arm, open label study of SV-BR-1-GM, a targeted immunotherapy for breast cancer. Eligible patients will have histological confirmation of breast cancer with recurrent and/or metastatic lesions. The treatment regimen includes a pre-treatment with low-dose cyclophosphamide 2-3 days before the inoculation; inoculation in 4 sites on the thighs and upper back; and post-treatment inoculation of Interferon-alpha-2b into the sites of inoculation \~2 and \~4 days after the inoculation. These is repeated every 2 weeks for one month (3 treatments), then monthly for up to one year. Standard tumor assessments are performed at baseline and then every 2-3 months.
Interventions
- DRUG Cyclophosphamide
- BIOLOGICAL SV-BR-1-GM
- BIOLOGICAL Interferon-alpha-2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-05-05 |
| Est. Completion | 2018-11-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03066947
The ClinicalTrials.gov registry entry for NCT03066947 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BriaCell Therapeutics Corporation, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT03066947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03066947 about?
NCT03066947 is a clinical study titled "SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer". This is a single arm, open label study of SV-BR-1-GM, a targeted immunotherapy for breast cancer. Eligible patients will have histological confirmation of breast cancer with recurrent and/or metastatic lesions. The treatment regimen includes a pre-treatment with low-dose cyclophosphamide 2-3 days be...
What is the current status of trial NCT03066947?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2017-05-05. Estimated completion is 2018-11-22.
What interventions are being tested in trial NCT03066947?
The interventions under investigation include: Cyclophosphamide (DRUG), SV-BR-1-GM (BIOLOGICAL), Interferon-alpha-2b (BIOLOGICAL).
Who is sponsoring clinical trial NCT03066947?
This trial is sponsored by BriaCell Therapeutics Corporation, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.